Novel Targeted Anti-Tumor Nanoparticles Developed from Folic Acid-Modified 2-Deoxyglucose

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Feb 10

PMID 30736291

Citations 7

Authors

Shaoming Jin

Zhongyao Du

Huiyuan Guo

Hao Zhang

Fazheng Ren

Pengjie Wang

Affiliations

Soon will be listed here.

Abstract

The glucose analog, 2-deoxyglucose (2-DG), specifically inhibits glycolysis of cancer cells and interferes with the growth of cancer cells. However, the excellent water solubility of 2-DG makes it difficult to be concentrated in tumor cells. In this study, a targeted nano-pharmacosome was developed with folic acid-modified 2-DG (FA-2-DG) by using amino ethanol as a cleavable linker. FA-2-DG was able to self-assemble, forming nano-particles with diameters of 10⁻30 nm. The biological effects were evaluated with cell viability assays and flow cytometry analysis. Compared with a physical mixture of folic acid and 2-DG, FA-2-DG clearly reduced cell viability and resulted in cell cycle arrest. A computational study involving docking simulation suggested that FA-2-DG can dock into the same receptor as folic acid, thus confirming that the structural modification did not affect the targeting performance. The results indicated that the nano-pharmacosome consisting of FA-2-DG can be used for targeting in a nano-drug delivery system.

Citing Articles

Engineering metabolism to modulate immunity.

Kapnick S, Martin C, Jewell C Adv Drug Deliv Rev. 2023; 204:115122.

PMID: 37935318 PMC: 10843796. DOI: 10.1016/j.addr.2023.115122.

Deoxyglucose-conjugated persistent luminescent nanoparticles for theragnostic application in fibrosarcoma tumor model.

Sharma K, Melwani P, Yadav H, Joshi R, Shetake N, Dubey A RSC Adv. 2023; 13(19):13240-13251.

PMID: 37123999 PMC: 10141588. DOI: 10.1039/d3ra01169k.

The Levels of TNF-, Tissue Factor, and Coagulation Function in Rats with Pulmonary Hypertension and the Intervention Effect of Sildenafil Encapsulated by Targeted Nanocarriers.

Ma X, Wang X, Xie L, Lu S, Jiang C Comput Math Methods Med. 2022; 2022:8619092.

PMID: 35602350 PMC: 9122730. DOI: 10.1155/2022/8619092.

Lipid-Based Nanovesicular Drug Delivery Systems.

Limongi T, Susa F, Marini M, Allione M, Torre B, Pisano R Nanomaterials (Basel). 2021; 11(12).

PMID: 34947740 PMC: 8707227. DOI: 10.3390/nano11123391.

Complexity of the Nano-Bio Interface and the Tortuous Path of Metal Oxides in Biological Systems.

Erlichman J, Leiter J Antioxidants (Basel). 2021; 10(4).

PMID: 33915992 PMC: 8066112. DOI: 10.3390/antiox10040547.

References

Gapstur S, Gann P, Lowe W, Liu K, Colangelo L, Dyer A . Abnormal glucose metabolism and pancreatic cancer mortality. JAMA. 2000; 283(19):2552-8. DOI: 10.1001/jama.283.19.2552. View

Zhu W, Ma D . Synthesis of aryl azides and vinyl azides via proline-promoted CuI-catalyzed coupling reactions. Chem Commun (Camb). 2004; (7):888-9. DOI: 10.1039/b400878b. View

Arap M, Lahdenranta J, Mintz P, Hajitou A, Sarkis A, Arap W . Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell. 2004; 6(3):275-84. DOI: 10.1016/j.ccr.2004.08.018. View

Gatenby R, Gillies R . Why do cancers have high aerobic glycolysis?. Nat Rev Cancer. 2004; 4(11):891-9. DOI: 10.1038/nrc1478. View

Kondoh H, LLeonart M, Gil J, Wang J, Degan P, Peters G . Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005; 65(1):177-85. View

Maher J, Savaraj N, Priebe W, Liu H, Lampidis T . Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas. 2005; 30(2):e34-9. DOI: 10.1097/01.mpa.0000153327.46945.26. View

Pelicano H, Martin D, Xu R, Huang P . Glycolysis inhibition for anticancer treatment. Oncogene. 2006; 25(34):4633-46. DOI: 10.1038/sj.onc.1209597. View

Kalli K, Oberg A, Keeney G, Christianson T, Low P, Knutson K . Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol. 2008; 108(3):619-26. PMC: 2707764. DOI: 10.1016/j.ygyno.2007.11.020. View

Diaz-Ruiz R, Rigoulet M, Devin A . The Warburg and Crabtree effects: On the origin of cancer cell energy metabolism and of yeast glucose repression. Biochim Biophys Acta. 2010; 1807(6):568-76. DOI: 10.1016/j.bbabio.2010.08.010. View

10.

Kumar A, Kumar V, Dere R, Schmidt R . Glycoside bond formation via acid-base catalysis. Org Lett. 2011; 13(14):3612-5. DOI: 10.1021/ol201231v. View

11.

Sottnik J, Lori J, Rose B, Thamm D . Glycolysis inhibition by 2-deoxy-D-glucose reverts the metastatic phenotype in vitro and in vivo. Clin Exp Metastasis. 2011; 28(8):865-75. DOI: 10.1007/s10585-011-9417-5. View

12.

Giammarioli A, Gambardella L, Barbati C, Pietraforte D, Tinari A, Alberton M . Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response. Int J Cancer. 2011; 131(4):E337-47. DOI: 10.1002/ijc.26420. View

13.

van Dam G, Themelis G, Crane L, Harlaar N, Pleijhuis R, Kelder W . Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results. Nat Med. 2011; 17(10):1315-9. DOI: 10.1038/nm.2472. View

14.

Zhang M, Guo R, Wang Y, Cao X, Shen M, Shi X . Multifunctional dendrimer/combretastatin A4 inclusion complexes enable in vitro targeted cancer therapy. Int J Nanomedicine. 2011; 6:2337-49. PMC: 3205130. DOI: 10.2147/IJN.S24705. View

15.

Zheng J . Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol Lett. 2012; 4(6):1151-1157. PMC: 3506713. DOI: 10.3892/ol.2012.928. View

16.

Chen C, Ke J, Zhou X, Yi W, Brunzelle J, Li J . Structural basis for molecular recognition of folic acid by folate receptors. Nature. 2013; 500(7463):486-9. PMC: 5797940. DOI: 10.1038/nature12327. View

17.

Urakami K, Zangiacomi V, Yamaguchi K, Kusuhara M . Impact of 2-deoxy-D-glucose on the target metabolome profile of a human endometrial cancer cell line. Biomed Res. 2013; 34(5):221-9. DOI: 10.2220/biomedres.34.221. View

18.

OByrne K, Baird A, Kilmartin L, Leonard J, Sacevich C, Gray S . Epigenetic regulation of glucose transporters in non-small cell lung cancer. Cancers (Basel). 2013; 3(2):1550-65. PMC: 3757377. DOI: 10.3390/cancers3021550. View

19.

Warmoes M, Locasale J . Heterogeneity of glycolysis in cancers and therapeutic opportunities. Biochem Pharmacol. 2014; 92(1):12-21. PMC: 4254151. DOI: 10.1016/j.bcp.2014.07.019. View

20.

Zhang D, Li J, Wang F, Hu J, Wang S, Sun Y . 2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy. Cancer Lett. 2014; 355(2):176-83. DOI: 10.1016/j.canlet.2014.09.003. View